WO2007109154A3 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof - Google Patents

Bicycloheteroaryl compounds as p2x7 modulators and uses thereof Download PDF

Info

Publication number
WO2007109154A3
WO2007109154A3 PCT/US2007/006676 US2007006676W WO2007109154A3 WO 2007109154 A3 WO2007109154 A3 WO 2007109154A3 US 2007006676 W US2007006676 W US 2007006676W WO 2007109154 A3 WO2007109154 A3 WO 2007109154A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulators
compounds
bicycloheteroaryl compounds
bicycloheteroaryl
formula
Prior art date
Application number
PCT/US2007/006676
Other languages
French (fr)
Other versions
WO2007109154A2 (en
Inventor
Michael G Kelly
John Kincaid
Yunfeng Fang
Yeyu Cao
Carl Kaub
Sumithra Gowlugari
Zhan Wang
Original Assignee
Renovis Inc
Michael G Kelly
John Kincaid
Yunfeng Fang
Yeyu Cao
Carl Kaub
Sumithra Gowlugari
Zhan Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovis Inc, Michael G Kelly, John Kincaid, Yunfeng Fang, Yeyu Cao, Carl Kaub, Sumithra Gowlugari, Zhan Wang filed Critical Renovis Inc
Priority to EP07753312A priority Critical patent/EP1996585A4/en
Priority to JP2009500513A priority patent/JP2009541205A/en
Priority to US12/225,276 priority patent/US20090298825A1/en
Priority to CA002645652A priority patent/CA2645652A1/en
Publication of WO2007109154A2 publication Critical patent/WO2007109154A2/en
Publication of WO2007109154A3 publication Critical patent/WO2007109154A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
PCT/US2007/006676 2006-03-16 2007-03-16 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof WO2007109154A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07753312A EP1996585A4 (en) 2006-03-16 2007-03-16 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
JP2009500513A JP2009541205A (en) 2006-03-16 2007-03-16 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US12/225,276 US20090298825A1 (en) 2006-03-16 2007-03-16 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
CA002645652A CA2645652A1 (en) 2006-03-16 2007-03-16 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US78292206P 2006-03-16 2006-03-16
US78277506P 2006-03-16 2006-03-16
US78278206P 2006-03-16 2006-03-16
US78374806P 2006-03-16 2006-03-16
US78359006P 2006-03-16 2006-03-16
US78277606P 2006-03-16 2006-03-16
US78297306P 2006-03-16 2006-03-16
US78330406P 2006-03-16 2006-03-16
US78312106P 2006-03-16 2006-03-16
US60/782,776 2006-03-16
US60/783,590 2006-03-16
US60/783,121 2006-03-16
US60/782,782 2006-03-16
US60/783,304 2006-03-16
US60/782,775 2006-03-16
US60/783,748 2006-03-16
US60/782,922 2006-03-16
US60/782,973 2006-03-16
US83141606P 2006-07-17 2006-07-17
US60/831,416 2006-07-17
US84699306P 2006-09-25 2006-09-25
US60/846,993 2006-09-25
US91812307P 2007-03-15 2007-03-15
US60/918,123 2007-03-15
US78292307P 2007-03-16 2007-03-16
US60/782,923 2007-03-16

Publications (2)

Publication Number Publication Date
WO2007109154A2 WO2007109154A2 (en) 2007-09-27
WO2007109154A3 true WO2007109154A3 (en) 2008-05-02

Family

ID=38522986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006676 WO2007109154A2 (en) 2006-03-16 2007-03-16 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof

Country Status (2)

Country Link
CA (1) CA2645652A1 (en)
WO (1) WO2007109154A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124562B1 (en) * 2007-03-09 2016-04-20 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
RU2010121763A (en) 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Pyridazinone derivatives and P2X7 receptor inhibitors
PT2105164E (en) 2008-03-25 2011-03-24 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
MX2011006475A (en) * 2008-12-16 2011-09-15 Sirtris Pharmaceuticals Inc Phthalazinone and related analogs as sirtuin modulators.
GB0906274D0 (en) 2009-04-09 2009-05-20 Ge Healthcare Ltd Imaging the central nervous system
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
BR112012028850A2 (en) 2010-05-14 2015-09-15 Affectis Pharmaceuticals Ag methods for preparing p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
JP5955957B2 (en) 2011-07-22 2016-07-20 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Heterocyclic amide derivatives as P2X7 receptor antagonists
SG11201403933UA (en) 2012-01-20 2014-08-28 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
KR102222220B1 (en) 2013-01-22 2021-03-03 이도르시아 파마슈티컬스 리미티드 Heterocyclic amide derivatives as p2x7 receptor antagonists
CN104918946B (en) 2013-01-22 2017-03-29 埃科特莱茵药品有限公司 As P2X7The heterocyclic amide derivative of receptor antagonist
US9938292B2 (en) * 2014-03-24 2018-04-10 Guangdong Zhongsheng Pharmaceutical Co., Ltd Quinoline derivatives as SMO inhibitors
KR20180017013A (en) 2015-05-06 2018-02-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-Ras modulator
SG11201909570PA (en) 2017-04-20 2019-11-28 Univ California K-ras modulators
TWI825637B (en) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135557A1 (en) * 2003-06-13 2006-06-22 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135557A1 (en) * 2003-06-13 2006-06-22 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1996585A4 *

Also Published As

Publication number Publication date
WO2007109154A2 (en) 2007-09-27
CA2645652A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2086540B8 (en) Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2005034870A3 (en) Amide compounds and ion channel ligands and uses thereof
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2008097640A3 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2008070268A3 (en) Pharmaceutical compositions
IL195030A (en) Dpp iv inhibitor formulations
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
EP2215054B8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008047061A3 (en) Cosmetic oral and/or parenteral use of glucosamine optionally in combination with at least one polyphenol compound, and corresponding composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753312

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2645652

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009500513

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007753312

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12225276

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)